Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics (NASDAQ: CORT) is set to announce its second quarter financial results and provide a corporate update on July 29, 2021, at 5:00 p.m. ET. The company, known for treating severe metabolic, oncologic, and psychiatric disorders through cortisol modulation, will host a conference call that day. Interested participants can join via a provided link or by dialing in 15 minutes prior to the call. A replay of the call will be available until August 12, 2021.
- Scheduled second quarter financial results release on July 29, 2021.
- Opportunity for investors to engage in a corporate update via conference call.
- None.
MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2021. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time.
Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call. The passcode will be 1482035.
A replay will be available through August 12, 2021 at 1-855-859-2056 from the United States and 1-404-537-3406 internationally. The passcode will be 1482035.
About Corcept Therapeutics Incorporated
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.
CONTACT:
Corcept Therapeutics
Investor Relations
ir@corcept.com
www.corcept.com
FAQ
When will Corcept Therapeutics report its second quarter financial results?
What time is the Corcept Therapeutics conference call on July 29, 2021?
How can I participate in the Corcept Therapeutics conference call?
Will there be a replay of the Corcept Therapeutics conference call?
What is the ticker symbol for Corcept Therapeutics?
